Loading…

CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus

BACKGROUND The aetiology of systemic lupus erythematosus (SLE) is still unknown. In several cases, however, chemicals or drugs were identified as aetiological agents and associations with certain phenotypes of drug metabolising enzymes have been reported. The purpose of this study was to discover if...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 1999-03, Vol.58 (3), p.182-185, Article 182
Main Authors: Kortunay, Selim, Bozkurt, Atila, Bathum, Lise, Basci, Nursabah E, Çalgüneri, Meral, Brøsen, Kim, Kayaalp, S Oḡuz
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND The aetiology of systemic lupus erythematosus (SLE) is still unknown. In several cases, however, chemicals or drugs were identified as aetiological agents and associations with certain phenotypes of drug metabolising enzymes have been reported. The purpose of this study was to discover if there is an association between CYP2C19 polymorphism and susceptibility to SLE. METHODS Racemic mephenytoin (100 mg orally) was given to healthy volunteers (n=161) and SLE patients (n=37) and then S-mephenytoin and R-mephenytoin were determined in eight hour urine samples. A 10 ml blood sample was obtained from healthy volunteers (n=80) and SLE patients (n=69) for genotypic assay. Each blood sample was tested for the detection ofCYP2C19*1 andCYP2C19*2 (formerly wt and m1 respectively) by oligonucleotide ligation assay. RESULTS The ratio of S/R-mephenytoin ranged from
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.58.3.182